At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2b Multicentre, Randomised, Double-Blind, Active-Controlled, Parallel Group Dose-Ranging Study to Assess the Efficacy, Safety and Tolerability of Zibotentan and Dapagliflozin in Patients With Chronic Kidney Disease With Estimated Glomerular Filtration Rate (eGFR) ≥ 20 mL/Min/1.73 m^2
In Brief
A Phase 2 clinical trial evaluating Zibotentan, Dapagliflozin, and 1 other intervention for Chronic Kidney Disease. Completed, enrolled 542 participants across 164 sites in 19 countries.
Detailed Summary
The purpose of the study is to assess efficacy, safety and tolerability of treatment with zibotentan and dapagliflozin in combination and dapagliflozin 10 mg as monotherapy in participants with chronic kidney disease (CKD) with estimated glomerular filtration rate (eGFR) ≥ 20 mL/min/1.73 m\^2, and urinary albumin to creatinine ratio (UACR) ≥ 150 mg/g and ≤ 5000 mg/g.
Study Details
Timeline
Interventions
Participants will receive zibotentan as per the arms they are randomized.
Participants will receive 10 mg dapagliflozin as per the arms they are randomized.
Participants will receive placebo as per the arms they are randomized to.